Market Place
Sourcing Support
Oryzon Presents Iadademstat Plus Gilteritinib Data At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
ORYZON`s Iadademstat ALICE Phase 2a Results Published In Lancet Hematology
03 Jun 2024 //
GLOBENEWSWIRE
ORYZON Announces FDA Clearance of Iadademstat for SCLC
08 Apr 2024 //
GLOBENEWSWIRE
ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat
15 Mar 2023 //
GLOBENEWSWIRE
ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat
16 Dec 2022 //
GLOBENEWSWIRE
ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients
12 Dec 2022 //
GLOBENEWSWIRE
ORYZON Enters CRADA with U.S. NCI to Develop Iadademstat in Different Cancers
19 Jul 2022 //
GLOBENEWSWIRE
Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in AML
10 Jun 2022 //
GLOBENEWSWIRE
ORYZON Announces FDA ODD Granted to Iadademstat for SCLC
08 Jun 2022 //
GLOBENEWSWIRE
ORYZON Awarded EU Seal of Excellence & Public Financing of $2M for Iadademstat
07 Jun 2022 //
GLOBENEWSWIRE
ORYZON Announces FDA Approval of IND for FRIDA With Iadademstat in R/R AML
21 Mar 2022 //
GLOBENEWSWIRE
US FDA grants orphan drug status to ORYZON’s iadademstat to treat acute myeloid
12 Feb 2021 //
PHARMABIZ
ORYZON Announces FDA Orphan Drug Designation Granted to iadademstat
11 Feb 2021 //
GLOBENEWSWIRE
ORYZON to Present Further +ve Efficacy Data From Iadademstat ALICE Ph IIa Trial
11 Nov 2020 //
GLOBENEWSWIRE
ORYZON Presents Efficacy and Safety Results of its CLEPSIDRA Trial
17 Sep 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.